The Association Between Neutrophil/High-Density Lipoprotein Cholesterol Ratio and Non-Alcoholic Fatty Liver Disease in a Healthy Population DOI Creative Commons

Zhuoya Jia,

Zelin Li, Shuchun Chen

et al.

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2024, Volume and Issue: Volume 17, P. 2597 - 2605

Published: June 1, 2024

Objective: Non-alcoholic fatty liver disease (NAFLD) is characterized by abnormal lipid metabolism and inflammation. This study aimed to investigate the relationship between neutrophil-HDL cholesterol ratio (NHR) NAFLD in a healthy population. Methods: 1881 people who underwent physical examination from August December 2023 at Hebei General Hospital were chosen for this cross-sectional study. 936 individuals ultimately included thanks propensity matching exclusion criteria. Ultrasound was used diagnose t -test or Mann–Whitney test compare clinical characteristics of participants groups with without liver. Logistic regression construct new model that NHR. The predictive value NHR as well population assessed using logistic subject work characteristic curves. Results: levels higher among group than those NAFLD(P< 0.05). risk factor population(P< odds ratios (ORs) predicting Model I (adjusted sex, age, BMI) II BMI, HbA1c, TC, TG, ALT) 1.166 (1.022, 1.331) 1.248 (1.110, 1.402)(P< created predicted an area under curve 0.676 (0.645, 0.706). Compared low group, high exhibited prevalence NAFLD(p< Conclusion: associated NAFLD, which good predictor Keywords: neutrophil/high-density lipoprotein ratio, nonalcoholic

Language: Английский

Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits DOI Creative Commons
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(4), P. 1136 - 1160

Published: June 22, 2022

Language: Английский

Citations

298
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease DOI
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 764 - 783

Published: Aug. 15, 2023

Language: Английский

Citations

94
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies DOI Creative Commons
Maurizio Parola, Massimo Pinzani

Molecular Aspects of Medicine, Journal Year: 2023, Volume and Issue: 95, P. 101231 - 101231

Published: Dec. 5, 2023

Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results from chronic liver injury well persistent activation inflammatory response and fibrogenesis. fibrosis is a major determinant for disease (CLD) progression in the last two decades our understanding on molecular cellular mechanisms underlying fibrogenic CLD has dramatically improved, boosting pre-clinical studies clinical trials designed to find novel therapeutic approaches. From these several critical concepts have emerged, starting reveal complexity pro-fibrotic microenvironment which involves very complex, dynamic interrelated interactions between different hepatic extrahepatic cell populations. This review will offer first recapitulation established pathophysiological basic principles by intentionally focus attention NAFLD/NASH, metabolic-related form with high impact general population emerging leading cause worldwide. NAFLD/NASH-related pro-inflammatory profibrogenic be analysed information cells, mediators signalling pathways taken advantage methodological approaches techniques (single genomics, imaging mass cytometry, vitro two- three-dimensional models, etc.). We next overview recent advancement diagnostic prognostic tools, including serum biomarkers polygenic scores, support analysis biopsies. Finally, this provide current therapies treatment NAFLD/NASH patients.

Language: Английский

Citations

62
Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice DOI Creative Commons
Jonathan M. Weiss, Erika M. Palmieri, Marieli Gonzalez-Cotto

et al.

Nature Metabolism, Journal Year: 2023, Volume and Issue: 5(6), P. 981 - 995

Published: June 12, 2023

Abstract Itaconate, the product of decarboxylation cis -aconitate, regulates numerous biological processes. We and others have revealed itaconate as a regulator fatty acid β-oxidation, generation mitochondrial reactive oxygen species metabolic interplay between resident macrophages tumors. In present study, we show that itaconic is upregulated in human non-alcoholic steatohepatitis mouse model liver disease. Male mice deficient gene responsible for production (immunoresponsive (Irg)-1) exacerbated lipid accumulation liver, glucose insulin intolerance mesenteric fat deposition. Treatment with derivative, 4-octyl itaconate, reverses dyslipidemia associated high-fat diet feeding. Mechanistically, treatment primary hepatocytes reduces increases their oxidative phosphorylation manner dependent upon oxidation. propose whereby macrophage-derived acts trans to modulate liver’s ability metabolize acids.

Language: Английский

Citations

45
Hepatic Stellate Cell-Immune Interactions in NASH DOI Creative Commons
James K. Carter, Scott L. Friedman

Frontiers in Endocrinology, Journal Year: 2022, Volume and Issue: 13

Published: June 9, 2022

Nonalcoholic fatty liver disease (NAFLD) is the dominant cause of worldwide. steatohepatitis (NASH), a more aggressive presentation NAFLD, characterized by severe hepatocellular injury, inflammation, and fibrosis. Chronic inflammation heightened immune cell activity have emerged as hallmark features NASH key drivers fibrosis through activation hepatic stellate cells (HSCs). Recent advances in our understanding molecular cellular pathways highlighted extensive crosstalk between HSCs populations that strongly influences activity. Here, we review these findings, emphasizing roles immunity cell-cell interactions, exciting areas for future investigation.

Language: Английский

Citations

52
From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences DOI Creative Commons
Ahmed Samy,

Mohamed A. Kandeil,

Dina Sabry

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(9), P. e30387 - e30387

Published: April 25, 2024

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic diseases worldwide in recent decades. Metabolic like excessive blood glucose, central obesity, dyslipidemia, hypertension, and function abnormalities cause NAFLD. NAFLD significantly increases likelihood cancer, heart disease, mortality, making it a leading transplants. steatohepatitis (NASH) is more advanced form that causes scarring inflammation over time can ultimately result cirrhosis hepatocellular carcinoma. In this review, we briefly discuss NAFLD's pathogenic mechanisms, their progression into NASH afterward to NASH-related cirrhosis. It also covers epidemiology, metabolic glucose lipid metabolism liver, macrophage dysfunction, bile acid toxicity, stellate cell stimulation. Additionally, consider contribution intestinal microbiota, genetics, epigenetics, ecological factors fibrosis carcinoma risk patients.

Language: Английский

Citations

13
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice DOI Open Access
Hassam Ali, Muhammad Shahzil, Vishali Moond

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(1), P. 61 - 61

Published: Jan. 1, 2024

This review provides a practical and comprehensive overview of non-pharmacological interventions for metabolic-associated fatty liver disease (MASLD), focusing on dietary exercise strategies. It highlights the effectiveness coffee consumption, intermittent fasting, Mediterranean ketogenic diets in improving metabolic health. The emphasizes importance combining aerobic resistance training as critical approach to reducing fat increasing insulin sensitivity. Additionally, it discusses synergy between diet enhancing parameters role gut microbiota MASLD. paper underscores need holistic, individualized approach, integrating diet, exercise, health, patient motivation. also long-term benefits minimal risks lifestyle compared side effects pharmacological surgical options. calls personalized treatment strategies, continuous education, further research optimize therapeutic outcomes MASLD management.

Language: Английский

Citations

12
Inflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets DOI Creative Commons
Dechun Feng, Seonghwan Hwang, Adrien Guillot

et al.

Cellular and Molecular Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 18(3), P. 101352 - 101352

Published: Jan. 1, 2024

Alcohol-associated hepatitis (AH) is an acute-on-chronic liver injury that occurs in patients with chronic alcohol-associated disease (ALD). Patients severe AH have high short-term mortality and lack effective pharmacologic therapies. Inflammation believed to be one of the key factors promoting progression has been actively investigated as therapeutic targets over last several decades, but no inflammatory identified so far. In this review, we discuss how cells mediators produced by these contribute development AH, focus on neutrophils macrophages. The crosstalk between nonparenchymal pathogenesis elaborated. We also deliberate application recent cutting-edge technologies characterizing inflammation AH. Finally, potential for are briefly summarized.

Language: Английский

Citations

10
The Interplay between Liver Sinusoidal Endothelial Cells, Platelets, and Neutrophil Extracellular Traps in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Iulia Minciună,

Madalina Gabriela Taru,

Bogdan Procopeţ

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(5), P. 1406 - 1406

Published: Feb. 29, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a societal burden due to the lack of effective treatment and incomplete pathophysiology understanding. This review explores intricate connections among sinusoidal endothelial cells (LSECs), platelets, neutrophil extracellular traps (NETs), coagulation disruptions in MASLD pathogenesis. In MASLD’s early stages, LSECs undergo capillarization dysfunction excessive dietary macronutrients gut-derived products. Capillarization leads ischemic changes hepatocytes, triggering pro-inflammatory responses Kupffer (KCs) activating hepatic stellate (HSCs). Capillarized show phenotype through adhesion molecule overexpression, autophagy loss, increased cytokines production. Platelet interaction favors leucocyte recruitment, NETs formation, inflammatory foci. Liver fibrosis is facilitated by reduced nitric oxide, HSC activation, profibrogenic mediators, angiogenesis. Moreover, platelet attachment, α-granule cargo release, formation contribute progression. Platelets foster microthrombosis, leading parenchymal extinction fibrotic healing. Additionally, platelets promote tumor growth, epithelial–mesenchymal transition, cell metastasis. prothrombotic features are exacerbated insulin resistance, diabetes, obesity, manifesting as von Willebrand factor, hyperaggregability, hypo-fibrinolysis, fibrin clot structure. Improving LSEC health using antiplatelet appear promising for preventing development

Language: Английский

Citations

8
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact DOI
Anna Alisi, Geoffrey W. McCaughan, Henning Grønbæk

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 861 - 872

Published: July 12, 2024

Language: Английский

Citations

8